Suppr超能文献

脑固有免疫反应在溶酶体贮积症中的作用:基本过程还是进化副产物?

The role of brain innate immune response in lysosomal storage disorders: fundamental process or evolutionary side effect?

机构信息

Department of Infectious Diseases, Israel institute for Biological Research, Ness-Ziona, Israel.

出版信息

FEBS Lett. 2020 Nov;594(22):3619-3631. doi: 10.1002/1873-3468.13980. Epub 2020 Nov 20.

Abstract

Sphingolipidoses are diseases caused by mutations in genes responsible for sphingolipid degradation and thereby lead to sphingolipid accumulation. Most sphingolipidoses have a neurodegenerative manifestation characterized by innate immune activation in the brain. However, the role of the immune response in disease progression is ill-understood. In contrast to infectious diseases, immune activation is unable to eliminate the offending agent in sphingolipidoses resulting in ineffective, chronic inflammation. This paradox begs two fundamental questions: Why has this immune response evolved in sphingolipidoses? What role does it play in disease progression? Here, starting from the observation that sphingolipids (SLs) are elevated also in infectious diseases, I discuss the possibility that the activation of the brain immune response by SLs has evolved as a part of the immune response against pathogens and plays no major role in sphingolipidoses.

摘要

鞘脂贮积症是由负责鞘脂降解的基因突变引起的疾病,从而导致鞘脂积累。大多数鞘脂贮积症都有神经退行性表现,其特征是大脑中先天免疫激活。然而,免疫反应在疾病进展中的作用还不清楚。与传染病不同,免疫激活无法消除鞘脂贮积症中的致病因子,导致无效的慢性炎症。这种矛盾提出了两个基本问题:为什么鞘脂贮积症中会出现这种免疫反应?它在疾病进展中起什么作用?在这里,我从鞘脂(SLs)在传染病中也升高的观察出发,讨论了 SLs 激活大脑免疫反应是否作为针对病原体的免疫反应的一部分而进化,而在鞘脂贮积症中不起主要作用的可能性。

相似文献

1
The role of brain innate immune response in lysosomal storage disorders: fundamental process or evolutionary side effect?
FEBS Lett. 2020 Nov;594(22):3619-3631. doi: 10.1002/1873-3468.13980. Epub 2020 Nov 20.
2
Innate immune responses in the brain of sphingolipid lysosomal storage diseases.
Biol Chem. 2015 Jun;396(6-7):659-67. doi: 10.1515/hsz-2014-0301.
3
Sphingolipids and neuronal degeneration in lysosomal storage disorders.
J Neurochem. 2019 Mar;148(5):600-611. doi: 10.1111/jnc.14540. Epub 2018 Aug 16.
4
Characterization of mutants as a model for lysosomal sphingolipid storage diseases.
Dis Model Mech. 2017 Jun 1;10(6):737-750. doi: 10.1242/dmm.027953. Epub 2017 Apr 7.
5
Pathology and current treatment of neurodegenerative sphingolipidoses.
Neuromolecular Med. 2010 Dec;12(4):362-82. doi: 10.1007/s12017-010-8133-7. Epub 2010 Aug 22.
6
My journey into the world of sphingolipids and sphingolipidoses.
Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(10):554-82. doi: 10.2183/pjab.88.554.
7
Sphingolipids and cell signalling.
J Inherit Metab Dis. 1998 Aug;21(5):472-80. doi: 10.1023/a:1005454602454.
9
Genetic defects in the sphingolipid degradation pathway and their effects on microglia in neurodegenerative disease.
Cell Signal. 2021 Feb;78:109879. doi: 10.1016/j.cellsig.2020.109879. Epub 2020 Dec 6.
10
A view on sphingolipids and disease.
Chem Phys Lipids. 2011 Sep;164(6):590-606. doi: 10.1016/j.chemphyslip.2011.04.013. Epub 2011 May 6.

引用本文的文献

2
Antiviral activity of glucosylceramide synthase inhibitors in alphavirus infection of the central nervous system.
Brain Commun. 2023 Mar 25;5(3):fcad086. doi: 10.1093/braincomms/fcad086. eCollection 2023.
4
Elevation in sphingolipid upon SARS-CoV-2 infection: possible implications for COVID-19 pathology.
Life Sci Alliance. 2021 Nov 11;5(1). doi: 10.26508/lsa.202101168. Print 2022 Jan.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验